Deciphering the Comprehensive Structure-Activity Relationship of Sunshinamide for Breast Cancer Therapy through Dual

Akash Chatterjee1, Joyanta Mondal2, Subhojit Paul1

  • 1School of Biological Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700032, India.

PubMed

Insights

Sunshinamide inhibits cancer growth by inducing both apoptosis and ferroptosis. This dual-action mechanism, targeting TrxR1 and Gpx4, shows promise for overcoming chemoresistance in breast cancer therapy.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Sunshinamide, a cyclodepsipeptide, exhibits anticancer properties.
  • Understanding the structure-activity relationship (SAR) of sunshinamide is crucial for its therapeutic development.
  • Existing research established the synthesis and preliminary anticancer effects of sunshinamide.

Purpose of the Study:

  • To elucidate the SAR of sunshinamide.
  • To investigate the mechanistic insights of sunshinamide's anticancer action in vitro and in vivo.
  • To explore sunshinamide's potential in overcoming chemoresistance.

Main Methods:

  • Structure-activity relationship (SAR) studies were conducted.
  • Mechanistic studies involved assessing targets such as TrxR1 and Gpx4.
  • In vitro and in vivo experiments evaluated apoptosis, reactive oxygen species (ROS) generation, ER-stress, lipid peroxidation, and ferroptosis induction.

Main Results:

  • SAR studies identified the bicyclic-ring and disulfide moiety as critical for anticancer activity.
  • Sunshinamide was found to target TrxR1, inducing ROS and ER-stress-mediated apoptosis.
  • Sunshinamide also targets Gpx4, promoting lipid peroxidation and ferroptosis.

Conclusions:

  • Sunshinamide effectively reduces tumor growth in vivo by inducing both apoptosis and ferroptosis.
  • The dual apoptotic and ferroptotic mechanisms highlight sunshinamide's potential as a novel breast cancer therapeutic.
  • Sunshinamide offers a promising strategy to address chemoresistance in cancer treatment.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
554
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.5K